Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib

Joensuu, Heikki; Blay, Jean‐Yves; Comandone, Alessandro; Martín‐Broto, Javier; Fumagalli, Elena; Grignani, Giovanni; García del Muro, Xavier; Adenis, Antoine; Valverde, Claudia; López–Pousa, Antonio; Bouché, Olivier; Italiano, Antoîne; Bauer, Sebastian; Barone, Carlo; Weiß, Claudia; Crippa, Stefania; Camozzi, Maura; Castellana, Ramon; Le Cesne, Axel

doi:10.1038/bjc.2017.290

Public

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib

Published in British Journal of Cancer • Aug 29, 2017

Authors:

Heikki Joensuu

Jean‐Yves Blay

Alessandro Comandone

Abstract

BACKGROUND: This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) refractory to imatinib or who do not tolerate imatinib. METHODS: , 5 days on/2 days off, until GIST progression or un...

Subject

Medicine

Tolerability

GiST

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!